Catalent Pharma Solutions CEO Talks IPO, Potential Biotech Bubble

Catalent Pharma Solutions begins trading on the New York Stock Exchange Thursday under the ticker CTLT. Catalent's president and chief executive officer John Chiminski tells TheStreet's Brittany Umar why the company says it's the number one drug delivery technology company in the world and how it supports big pharmaceutical names like Johnson & Johnson and GlaxoSmithKline. In light of Federal Reserve chair Janet Yellen's recent comments that some firms in the biotech industry appear to have stretched valuations, Chiminski also offers his thoughts on whether a bubble is forming in the biotech sector.